Breast Cancer Now media statements

We respond to breast cancer becoming the most common cancer globally

Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said:

We respond to draft NICE decision not to recommend abemaciclib with fulvestrant for routine use on the NHS

The National Institute for Health and Care Excellence (NICE) has today announced its decision to provisionally not recommend breast cancer t...

We welcome NICE approval of ribociclib with fulvestrant for use on the NHS

The National Institute for Health and Care Excellence (NICE) has today announced its decision to approve ribociclib with fulvestrant for rou...